|
Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
April 24, 2007A naturally occurring compound found in many fruits and vegetables as well as red wine, selectively kills leukemia cells in culture while showing no discernible toxicity against healthy cells, according to a study by researchers at the University of Pittsburgh School of Medicine. These findings, which were published online March 20 in the Journal of Biological Chemistry and will be in press on May 4, offer hope for a more selective, less toxic therapy for leukemia.
"Current treatments for leukemia, such as chemotherapy and radiation, often damage healthy cells and tissues and can produce unwanted side effects for many years afterward. So, there is an intensive search for more targeted therapies for leukemia worldwide," said corresponding author Xiao-Ming Yin, M.D., Ph.D., associate professor of pathology, University of Pittsburgh School of Medicine.
Leukemia is not a single disease but a number of related cancers that start in the blood-forming cells of the bone marrow. Meaning literally "white blood" in Greek, leukemia occurs when there is an excess of abnormal white blood cells. There are both acute and chronic forms of leukemia, each with many subtypes that vary in their response to treatment. According to the National Cancer Institute, about 44,000 new leukemia cases will be diagnosed in the United States in 2007, and there will be about 22,000 leukemia-related deaths.
Based on previous reports that anthocyanidins, a group of naturally occurring compounds widely available in fruits and vegetables as well as red wine, have chemopreventive properties, Dr. Yin and his collaborators studied the effects and the mechanisms of the most common type of a naturally modified anthocyanidin, known as cyanidin-3-rutinoside, or C-3-R, which was extracted and purified from black raspberries, in several leukemia and lymphoma cell lines.
They found that C-3-R caused about 50 percent of a human leukemia cell line known as HL-60 to undergo programmed cell death, or apoptosis, within about 18 hours of treatment at low doses. When they more than doubled the concentration of C-3-R, virtually all of the leukemia cells became apoptotic and died. C-3-R also induced apoptosis in other human leukemia and lymphoma cell lines.
When the investigators studied the mechanism of cell death in the leukemia cells, they found that C-3-R induced the accumulation of peroxides, a highly reactive form of oxygen, which, in turn, activated a mitochondria-mediated apoptotic pathway. Mitochondria are specialized structures located within all cells in the body that contain enzymes needed by the cell to metabolize foodstuffs into energy sources. In contrast, when the researchers treated normal human blood cells with C-3-R, they did not find any increased accumulation of reactive oxygen species and there were no apparent toxic effects on these cells.
Previous studies have shown that C-3-R possesses strong antioxidant activities, a characteristic shared by other polyphenols, such as those found in green tea, which could be responsible for their chemoprevention effects. Dr. Yin's work suggests that although C-3-R demonstrates antioxidant effects in the normal cells, it paradoxically induces an oxidative "stress" in the tumor cells. It is possible that this differential effect of C-3-R may account for its selective toxicity in the tumor cells.
According to Dr. Yin, these results indicate that C-3-R has the promising potential to be used in leukemia therapy with the advantages of being highly selective against cancer cells. "Because this compound is widely available in foods, it is very likely that it is not toxic even in purified form. Therefore, if we can reproduce these anti-cancer effects in animal studies, this will present a very promising approach for treating a variety of human leukemias and, perhaps, lymphomas as well."
University of Pittsburgh Schools of the Health Sciences
Based on previous reports that anthocyanidins, a group of naturally occurring compounds widely available in fruits and vegetables as well as red wine, have chemopreventive properties, Dr. Yin and his collaborators studied the effects and the mechanisms of the most common type of a naturally modified anthocyanidin, known as cyanidin-3-rutinoside, or C-3-R, which was extracted and purified from black raspberries, in several leukemia and lymphoma cell lines.
They found that C-3-R caused about 50 percent of a human leukemia cell line known as HL-60 to undergo programmed cell death, or apoptosis, within about 18 hours of treatment at low doses. When they more than doubled the concentration of C-3-R, virtually all of the leukemia cells became apoptotic and died. C-3-R also induced apoptosis in other human leukemia and lymphoma cell lines.
When the investigators studied the mechanism of cell death in the leukemia cells, they found that C-3-R induced the accumulation of peroxides, a highly reactive form of oxygen, which, in turn, activated a mitochondria-mediated apoptotic pathway. Mitochondria are specialized structures located within all cells in the body that contain enzymes needed by the cell to metabolize foodstuffs into energy sources. In contrast, when the researchers treated normal human blood cells with C-3-R, they did not find any increased accumulation of reactive oxygen species and there were no apparent toxic effects on these cells.
Previous studies have shown that C-3-R possesses strong antioxidant activities, a characteristic shared by other polyphenols, such as those found in green tea, which could be responsible for their chemoprevention effects. Dr. Yin's work suggests that although C-3-R demonstrates antioxidant effects in the normal cells, it paradoxically induces an oxidative "stress" in the tumor cells. It is possible that this differential effect of C-3-R may account for its selective toxicity in the tumor cells.
According to Dr. Yin, these results indicate that C-3-R has the promising potential to be used in leukemia therapy with the advantages of being highly selective against cancer cells. "Because this compound is widely available in foods, it is very likely that it is not toxic even in purified form. Therefore, if we can reproduce these anti-cancer effects in animal studies, this will present a very promising approach for treating a variety of human leukemias and, perhaps, lymphomas as well."
University of Pittsburgh Schools of the Health Sciences
Leukemia News and Current Leukemia Events RSSMcGill researchers overcome chemotherapy resistance in the lab
Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI).
Crucial Factors in Lymphoma Development and Survival Discovered
Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer.
Leukemia drug could save lives of stroke patients
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms.
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
Math could help cure leukemia
When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.
Combining math and medicine to treat leukemia
Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML).
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
Shilatifard Lab Identifies New Role for Factor Critical to Transcription
The Stowers Institute's Shilatifard Lab has identified a new role for the elongation factor ELL in gene transcription by RNA polymerase II (Pol II) - the enzyme that synthesizes messenger RNA to carry genetic information from DNA to the protein-synthesizing machinery of the cell.
Effective treatment for sickle cell underused by doctors
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Ability to track stem cells in tumors could advance cancer treatments
Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms.
More Leukemia News Articles
 | My Sister's Keeper: A Novel by Jodi Picoult |
 | Drums, Girls, And Dangerous Pie by Jordan Sonnenblick |
 | It's Only Temporary: The Good News and the Bad News of Being Alive by Evan Handler |
 | Sadako and the Thousand Paper Cranes (PMC) (Puffin Modern Classics) by Eleanor Coerr |
 | The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia and Other Seemingly Incurable Diseases by Rudolf Breuss |
 | Gideon's Gift (The Red Gloves Collection #1) by Karen Kingsbury |
 | One Thousand Paper Cranes: The Story of Sadako and the Children's Peace Statue by Takayuki Ishii |
 | The Rainmaker by John Grisham |
 | Time on Fire: My Comedy of Terrors by Evan Handler |
 | Childhood Leukemia: A Guide for Families, Friends and Caregivers (3rd Edition) by Nancy Keene |
| © 2008 BrightSurf.com |